company background image
DTC logo

Defence Therapeutics CNSX:DTC Stock Report

Last Price

CA$1.72

Market Cap

CA$76.6m

7D

0%

1Y

-52.2%

Updated

26 Mar, 2024

Data

Company Financials

Defence Therapeutics Inc.

CNSX:DTC Stock Report

Market Cap: CA$76.6m

DTC Stock Overview

Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases.

DTC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Defence Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Defence Therapeutics
Historical stock prices
Current Share PriceCA$1.72
52 Week HighCA$3.85
52 Week LowCA$1.60
Beta1.5
1 Month Change-9.47%
3 Month Change-28.03%
1 Year Change-52.22%
3 Year Changen/a
5 Year Changen/a
Change since IPO-32.81%

Recent News & Updates

Recent updates

We're Hopeful That Defence Therapeutics (CSE:DTC) Will Use Its Cash Wisely

Sep 08
We're Hopeful That Defence Therapeutics (CSE:DTC) Will Use Its Cash Wisely

Shareholder Returns

DTCCA BiotechsCA Market
7D0%-1.8%0.2%
1Y-52.2%-28.6%9.0%

Return vs Industry: DTC underperformed the Canadian Biotechs industry which returned -27.7% over the past year.

Return vs Market: DTC underperformed the Canadian Market which returned 9.3% over the past year.

Price Volatility

Is DTC's price volatile compared to industry and market?
DTC volatility
DTC Average Weekly Movement9.1%
Biotechs Industry Average Movement13.5%
Market Average Movement8.6%
10% most volatile stocks in CA Market18.5%
10% least volatile stocks in CA Market3.1%

Stable Share Price: DTC's share price has been volatile over the past 3 months.

Volatility Over Time: DTC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aSebastien Plouffehttps://defencetherapeutics.com

Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.

Defence Therapeutics Inc. Fundamentals Summary

How do Defence Therapeutics's earnings and revenue compare to its market cap?
DTC fundamental statistics
Market capCA$76.56m
Earnings (TTM)-CA$13.59m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DTC income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$13.59m
Earnings-CA$13.59m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-63.9%

How did DTC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.